Navigation Links
HeartWare Schedules Third Quarter Conference Call and Webcast
Date:10/21/2011

FRAMINGHAM, Mass. and SYDNEY, Oct. 21, 2011 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR, ASX:HIN) has scheduled a conference call to discuss its financial results for the three and nine months ended September 30, 2011, at 8:00 am U.S. Eastern Daylight Time on Friday, October 28, 2011 (being 11:00 pm Australian Eastern Daylight Time, Friday, October 28, 2011). The Company plans to release the financial results prior to the conference call.

The conference call with management will discuss the Company's financial results, highlights from the quarter and business outlook.  The call may be accessed by dialing 1-877-941-2068 five minutes prior to the scheduled start time and referencing "HeartWare."  For callers outside the U.S., please dial +1-480-629-9712.

A live webcast of the call will also be available at the Company's website (www.heartware.com) by selecting "HeartWare Third Quarter 2011 Conference Call" under the section titled "Corporate Presentations" on the Home Page.  A replay of the conference call will be available through the above weblink immediately following completion of the call.

A copy of the news release announcing results and related information will be available on the Company's web site, www.heartware.com.

About HeartWare International

HeartWare International develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat Class IIIB / IV patients suffering from advanced heart failure.  The HeartWare® Ventricular Assist System features the HVAD® Pump, a small full-output circulatory support device (up to 10L/min flow) designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices.  HeartWare has received CE Marking for the HeartWare System in the European
'/>"/>

SOURCE HeartWare International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. U.S. Federal Trade Commission to Challenge Thoratecs Proposed Acquisition of HeartWare International
2. HeartWare International, Inc. Temporary Suspension of Trading
3. HeartWare to Present at the 22nd Annual Piper Jaffray Health Care Conference
4. HeartWare to Report 2010 Fourth Quarter and Year-End Financial Results
5. HeartWare Completes GLP Studies of Next Generation MVAD® Pump; Data Presented Today at ISRBP Congress
6. HeartWare to Present at the UBS Global Life Sciences Conference
7. Sinovac Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders
8. Cyprus and Ireland Add Wyeths 7-Valent Pneumococcal Conjugate Vaccine (PCV7) to Their National Immunisation Schedules
9. Cepheid Schedules Fiscal 2008 Third Quarter Financial Results Announcement and Webcast
10. 3SBio Inc. Schedules 2008 Third Quarter Earnings Release on Monday, November 10, 2008
11. Bunge Limited Schedules Third Quarter 2008 Earnings Release and Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... NEW YORK , Aug. 27, 2014 ... market research report is available in its ... Market 2014-2018 http://www.reportlinker.com/p02316661/Global-Biodegradable-Packaging-Materials-Market-2014-2018.html ... Biodegradable materials are materials that are readily ... packaging differs from conventional non-degradable packaging in ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 The Global ... in-depth study on the current state of the Trifluoroacetic ... provides a basic overview of the industry, including definitions, ... Chinese domestic market analysis are provided with a focus ... market. A comparison between the international and Chinese situation ...
(Date:8/27/2014)... 27, 2014  Lisa Kulik saw fireworks for the ... holiday, thanks to a groundbreaking retinal implant co-invented by ... clinician-researcher at the University of Southern California (USC) Eye ... Peoria, Ariz. resident who has retinitis pigmentosa, ... sight. On June 2, she became the first person ...
(Date:8/27/2014)... 2014 Guggenheim Securities, the investment banking and ... hiring of veteran equity analyst Charles "Tony" Butler as ... will focus on the biotech/biopharma sector. " ... experience and a broad network of relationships in his ... and Head of Equities at Guggenheim Securities. "His insights ...
Breaking Biology Technology:Global Biodegradable Packaging Materials Market 2014-2018 2Global Biodegradable Packaging Materials Market 2014-2018 3Global Biodegradable Packaging Materials Market 2014-2018 4Global Biodegradable Packaging Materials Market 2014-2018 5Global Biodegradable Packaging Materials Market 2014-2018 6Global Biodegradable Packaging Materials Market 2014-2018 7Trifluoroacetic Acid Industry (Asia, Europe, North America, ROW) Analysis Report Now Available at ReportsnReports.com 2USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 2USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 3USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 4USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 5Guggenheim Securities Hires Analyst Charles "Tony" Butler to Expand Healthcare Coverage 2
... Patients Achieved an Objective Tumor Response by End of ... Inc. (Nasdaq: PPHM ) today reported that ... endpoint in the first stage of its ongoing Phase ... cancer (NSCLC). The open-label, Simon two-stage study is ...
... Bulletin Board: GOVX), an Atlanta-based, publicly traded,biopharmaceutical company developing ... and other infectious agents, today,announced that its Corporate Presentation ... webcast live by Thomson Reuters. The Conference will be ... February 9 and 10, 2009. , ...
... Wis., Feb. 4 Mach One Corporation (Pink Sheets: ... develops biotechnology based solutions that produce positive, long term ... that it has signed a definitive agreement to acquire ... company that supplies ingredients to the food, feed and ...
Cached Biology Technology:Peregrine Pharmaceuticals' Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study 2Peregrine Pharmaceuticals' Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study 3Peregrine Pharmaceuticals' Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study 4GeoVax to Webcast Its Presentation at the BIO CEO & Investor 2009 Conference 2GeoVax to Webcast Its Presentation at the BIO CEO & Investor 2009 Conference 3Mach One Corporation Signs Definitive Agreement to Acquire Ceres Organic Harvest, Inc. 2
(Date:8/28/2014)... conserve biodiversity and more action is needed to ensure ... say. , Published in PLOS ONE , researchers ... Exeter, used meta-analysis - combining results from different studies ... research into these areas, to determine whether they actually ... Biological Sciences, said protecting an area from human exploitation ...
(Date:8/27/2014)... Wis. The mechanical force that a single fungal cell ... vanishingly small, but it plays a heavy role in setting ... In fact, it may not be too much of a ... land without the ability to respond to the touch of ... An, a professor of agronomy at the University of Wisconsin-Madison. ...
(Date:8/27/2014)... in understanding the mysteries of the human genome was ... provide the most detailed comparison yet of how the ... , The research, appearing August 28 in in ... encoded in the three species, genomes is "read out," ... chromosomes. , The results add billions of entries to ...
Breaking Biology News(10 mins):Protected areas proven to protect biodiversity 2A touching story: The ancient conversation between plants, fungi and bacteria 2A touching story: The ancient conversation between plants, fungi and bacteria 3Encyclopedia of how genomes function gets much bigger 2Encyclopedia of how genomes function gets much bigger 3Encyclopedia of how genomes function gets much bigger 4
... (May 24, 2010) The timing of umbilical cord clamping ... suggest researchers at the University of South Florida,s Center of ... umbilical cord for a slightly longer period of time allows ... infant and, with that critical period extended, many good physiological ...
... , WALL, N.J. , May 24 BIO-key ... identification solutions, today announced that Evidian has integrated BIO-key,s biometric software ... deployed this biometric identification solution at two major pharmaceutical companies. , ... (Logo: http://www.newscom.com/cgi-bin/prnh/20050509/BIOKEYLOGO ...
... Israel Current research suggests that T helper-type ... actual inhibit the development of experimental immune encephalomyelitis (EAE), ... Th17 cells. The related report by Wildbaum et ... high CD4 + T cells restrain ...
Cached Biology News:Do we clamp the umbilical cord too soon? 2Do we clamp the umbilical cord too soon? 3BIO-key(R) Biometric Identification Now Incorporated Into Evidian Enterprise Single Sign-On Solution 2BIO-key(R) Biometric Identification Now Incorporated Into Evidian Enterprise Single Sign-On Solution 3BIO-key(R) Biometric Identification Now Incorporated Into Evidian Enterprise Single Sign-On Solution 4When helper cells aren't helpful 2
...
cysteine and glycine-rich protein 2,...
... Antitumour agent and DNA-topoisomersae II inhibitor (IC50 = ... C 29 H 32 O 13 ... Store at: RT ... Solubility: Soluble to 100 ...
HSPBP1 Antibody...
Biology Products: